Cadrenal Therapeutics holds annual stockholder meeting
CVKD•Cadrenal Therapeutics held its annual stockholder meeting on Sept. 24, 2026. Shareholders approved an increase of 323,542 shares in the 2022 Successor Equity Incentive Plan pool, bringing it to 1 million, and authorized issuing up to 960,000 common shares upon exercise of Series C-1 warrants.
1. Meeting approvals
Stockholders ratified WithumSmith+Brown as the independent registered public accounting firm for the year ending Dec. 31, 2026. The plan amendment authorizes a larger share pool but does not confirm any awards have been granted; issuance of the 960,000 shares depends on warrant exercises.
